Progress of immune checkpoint inhibitors in gastric cancer

Table 1 Immune checkpoint inhibitors approved by the Food and Drug Administration for gastric cancer

Drug	Brand name	Target	Medication regimen	Indication	Ref.
Nivolumab	Opdivo	PD-1	Alone	Stage II/III GC/GEJ with residual pathological tissue after neoadjuvant chemoradiotherapy	Kelly et al[10]
Nivolumab	Opdivo	PD-1	Nivolumab combined with chemotherapy (leucovorin, fluorouracil, and oxaliplatin or capecitabine and oxaliplatin)	Advanced metastatic HER-2-negative GC/GEJ	Janjigian et al[11]
Pembrolizumab	Keytruda	PD-1	Pembrolizumab combined with chemotherapy (cisplatin and 5-FU)	Locally advanced metastatic GC/GEJ	Sun et al[12]
Pembrolizumab	Keytruda	PD-1	Pembrolizumab combined with chemotherapy (platinum and fluoropyrimidine) and Trastuzumab	Locally advanced metastatic unresectable HER-2-positive GC/GEJ	Janjigian et al[13]
Pembrolizumab	Keytruda	PD-1	Pembrolizumab with chemotherapy (oxaliplatin with capecitabine or cisplatin and 5-FU)	Locally advanced metastatic HER-2-negative GC/GEJ	Rha et al[14]

GC/GEJ: Gastric cancer/gastroesophageal junction; HER-2: Human epidermal growth factor receptor 2; PD-1: Programmed death 1; 5-FU: 5-fluorouracil.